



SPARC/Sec/SE/2022/019

June 01, 2022

**National Stock Exchange of India Ltd.,**  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051.

**BSE Limited,**  
Market Operations Dept.  
P. J. Towers,  
Dalal Street,  
Mumbai - 400 001.

**Ref:** Scrip Code: NSE: SPARC; BSE: 532872

Dear Sir/Madam,

**Sub: Disclosure under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

---

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit disclosure of Related Party Transactions for the half year ended March 31, 2022

We request you to kindly take the same on record and disseminate.

Thanking you,

Yours faithfully,

For **Sun Pharma Advanced Research Company Limited**

**Dinesh Lahoti**  
**Company Secretary and Compliance Officer**  
**ICSI Membership No. A22471**

**Encl: As above**





**SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED**

**Disclosure on Related Party Transaction under Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended March 31, 2022**

Amount in Rs. Lakhs

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction	Details of the counterparty		Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period Oct - Mar 2022	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments			
		Name	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance (As at October 01, 2021)	Closing balance (As at March 31, 2022)	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured
19	Sun Pharma Advanced Research Company Limited	Sun Pharma Laboratories Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Sale of services - R&D services	195.62	97.16	-	-	-	-	-	-	-	-	-
20	Sun Pharma Advanced Research Company Limited	Sun Pharma Laboratories Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Purchase of Goods*	500.00	2.19	-	-	-	-	-	-	-	-	-
21	Sun Pharma Advanced Research Company Limited	Sun Pharma Laboratories Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Balance Receivable	N.A.	N.A.	1,228.35	1,372.78	-	-	-	-	-	-	-
22	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Europe BV	Enterprises under significant influence/are controlled by Key Management Personnel	Reimbursement of expenses paid*	500.00	2.67	-	-	-	-	-	-	-	-	-
23	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Europe BV	Enterprises under significant influence/are controlled by Key Management Personnel	Balance payable	N.A.	N.A.	14.54	16.97	-	-	-	-	-	-	-
24	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Inc.	Enterprises under significant influence/are controlled by Key Management Personnel	Reimbursement of expenses paid*	500.00	57.71	-	-	-	-	-	-	-	-	-
25	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Inc.	Enterprises under significant influence/are controlled by Key Management Personnel	Receiving of services - R&D Service	2,091.12	891.57	-	-	-	-	-	-	-	-	-
26	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Inc.	Enterprises under significant influence/are controlled by Key Management Personnel	Purchase of Goods*	500.00	4.23	-	-	-	-	-	-	-	-	-
27	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Inc.	Enterprises under significant influence/are controlled by Key Management Personnel	Balance payable	N.A.	N.A.	2,083.62	1,681.54	-	-	-	-	-	-	-



**SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED**

**Disclosure on Related Party Transaction under Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended March 31, 2022**

Amount in Rs. Lakhs

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction	Details of the counterparty		Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period Oct - Mar 2022	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments			
		Name	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance (As at October 01, 2021)	Closing balance (As at March 31, 2022)	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured
37	Sun Pharma Advanced Research Company Limited	Taro Pharmaceuticals Industries Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Sale of services - R&D services	14.42	12.31	-	-	-	-	-	-	-	-	-
38	Sun Pharma Advanced Research Company Limited	Taro Pharmaceuticals Industries Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Balance Receivable	N.A.	N.A.	1.25	11.38	-	-	-	-	-	-	-

Note :

N.A. denotes Not Applicable

Values mentioned under the column "Value of the related party transactions as approved by the Audit Committee" are for FY22 except for multi year related party transactions, which are tagged separately

# Represent aggregate value of multi year related party transaction

@ Approval granted by the audit committee in foreign currency are disclosed in INR, basis the closing exchange rate as on March 31, 2022

\* These transactions are also within the limits of overall aggregate omnibus limit granted by the Audit Committee